May Diabetes Dispatch

Latest Industry News

Scientists Estimate Higher Rate of New-Onset Diabetes After COVID than in the General Population

In a study published in Emerging Microbes & Infections, researchers from Weill Cornell Medicine–Qatar reviewed 35 global studies and found that 1.37% of COVID-19 patients developed new-onset diabetes, with most cases being type 2. The review included data from 4.4 million patients and identified several risk factors, including severity of infection, viral variant, existing health conditions, demographics, and vaccination status.

Full Article: CIDRAP

Low Blood Sugars (as well as high) cause Blindness in Diabetics

New research from Johns Hopkins Medicine’s Wilmer Eye Institute shows that not only high blood sugar, but also low blood sugar, can worsen diabetic eye disease. In a study on diabetic mice, researchers found that hypoglycemia triggered harmful protein activity in the retina, leading to vision-threatening damage. The team identified an experimental drug that successfully prevented retinal damage when given before low blood sugar episodes, suggesting that targeting HIF proteins could be a promising approach to prevent or treat diabetic retinopathy and support future human trials of the drug.

Full Article: New Atlas

Online Diabetes Nutrition Education is an Effective Tool

In the U.S., about 38 million people have diabetes, with most cases being type 2. Rates are highest among older adults and certain racial and ethnic groups. Globally, 1 in 9 adults has the disease, with many undiagnosed. A new study from Barnard Medical Center tested a 12-week online plant-based nutrition program for adults with type 2 diabetes. Participants saw reductions in body weight (−3.7 kg), HbA1c (−0.6%), cholesterol, and medication use. Those new to plant-based eating saw the greatest improvements, suggesting virtual dietary support can be an effective tool in diabetes care.

Full Article: WorldHealth.net 

Do you have an industry update to share? Submit to business@orangebiomed.com or post as a comment below.

ORANGE BIOMED LAUNCHES FIRST CITY-WIDE PUBLIC COMMUNITY HEALTH EVENT: M.A.P. YOUR HEALTH CHICAGO

“In the heart of Illinois—its capital, Chicago—we are calling on local organizations to join us in providing programming to make health tools and education more accessible, especially for communities disproportionately impacted,” - Yeaseul Park, CEO of Orange Biomed.

Learn more in our latest press release here.

Company Updates

M.A.P. Your Health

On May 15th, Orange Biomed sponsored our first live webinar, “Solving Healthcare Challenges,” presented by BDMT Global , where U.S. healthcare leaders and experts Ny'Nika McFadden, PhD , Pat Merryweather-Arges , John Robitscher, MPH , and event moderator Stacey Simms joined Orange Biomed Co-Founder and CEO Yeaseul Park to explore the gap between healthcare providers and patients, highlighting how informed education and early detection contribute to improved health outcomes.

At the live webinar, Orange Biomed announced the launch of “M.A.P Your Health: Monitor. Adapt. Prevent,” a nationwide campaign aimed at empowering community members to monitor their risk factors for chronic disease. In collaboration with local healthcare leaders, M.A.P. Your Health highlights the importance of health literacy and early monitoring to close gaps in care and prevent long-term complications by establishing a community education hub. Learn more here.

Interested in meeting with or interviewing Orange Biomed? Email shannon@orangebiomed.com to schedule time with company leadership to learn more about our innovation.

Practice News

Orange Biomed Presents Korean Diabetes Association’s Annual Meeting

Dr. Jieung Oh from Orange Biomed presented at the 38th Annual Scientific Meeting of the Korean Diabetes Association, introducing a groundbreaking approach to HbA1c testing using a microfluidic biosensor. The compact device offers a new paradigm for diabetes management, bringing lab-quality testing closer to patients.

Breakthrough T1D Triangle Gala 2025

In May, Orange Biomed Co-Founder and Managing Director Luke Jo attended the Breakthrough T1D Raleigh Gala in support of Breakthrough T1D North Carolina’s mission to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes and its complications.The gala raised $1,270,362 total for diabetes vital research, and we were honored to connect with and hear from Vertex Pharmaceuticals, Pegasystem, TD1 Advocate Ryan Reed, and many others who share our commitment to fighting diabetes. 

Read More